Barclays PLC Increases Position in CARGO Therapeutics, Inc. (NASDAQ:CRGX)

Barclays PLC boosted its holdings in CARGO Therapeutics, Inc. (NASDAQ:CRGX) by 226.7% in the third quarter, HoldingsChannel reports. The firm owned 56,354 shares of the company’s stock after purchasing an additional 39,102 shares during the period. Barclays PLC’s holdings in CARGO Therapeutics were worth $1,039,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of CRGX. Yu Fan acquired a new stake in shares of CARGO Therapeutics in the 2nd quarter valued at about $14,975,000. Geode Capital Management LLC raised its stake in CARGO Therapeutics by 80.6% during the third quarter. Geode Capital Management LLC now owns 838,279 shares of the company’s stock valued at $15,469,000 after buying an additional 374,018 shares in the last quarter. Novo Holdings A S lifted its holdings in CARGO Therapeutics by 23.5% during the 2nd quarter. Novo Holdings A S now owns 1,544,000 shares of the company’s stock worth $25,352,000 after buying an additional 294,000 shares during the last quarter. Perceptive Advisors LLC grew its position in shares of CARGO Therapeutics by 6.8% in the 2nd quarter. Perceptive Advisors LLC now owns 3,683,004 shares of the company’s stock worth $60,475,000 after acquiring an additional 235,000 shares in the last quarter. Finally, Sio Capital Management LLC bought a new stake in shares of CARGO Therapeutics in the 3rd quarter valued at approximately $3,208,000. Institutional investors and hedge funds own 93.16% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Chardan Capital restated a “buy” rating and set a $28.00 price objective on shares of CARGO Therapeutics in a research note on Wednesday, November 13th. William Blair started coverage on shares of CARGO Therapeutics in a research report on Tuesday, November 26th. They issued an “outperform” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $33.00 price objective on shares of CARGO Therapeutics in a research report on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $31.80.

CARGO Therapeutics Stock Down 7.1 %

Shares of NASDAQ CRGX opened at $11.18 on Wednesday. CARGO Therapeutics, Inc. has a 1-year low of $10.91 and a 1-year high of $33.92. The business’s fifty day moving average price is $16.10 and its two-hundred day moving average price is $17.69.

CARGO Therapeutics (NASDAQ:CRGX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.26. As a group, equities research analysts anticipate that CARGO Therapeutics, Inc. will post -3.73 EPS for the current fiscal year.

CARGO Therapeutics Profile

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.